Related coverage linked through entity extraction aliases.
Jul 30, 2026
A study in Cancer Cell reveals that immature NK cells in donor cord blood can sabotage CAR NK cell therapy through trogocytosis, causing fratricide. Removing these cells before manufacturing improves antitumor activity in preclinical models, offering a strategy for more consistent off-the-shelf therapies.
Jul 16, 2026
A deep learning pathomics platform called Path-IO accurately predicted outcomes and immunotherapy response in NSCLC patients using routine pathology slides, outperforming the PD-L1 biomarker. The model was validated across multiple cohorts and improved further when combined with radiomics and clinical data. If validated, it could be easily integrated into clinical workflows.
Jun 14, 2026
Patients with stage 4 lung, sarcoma, and gastro-oesophageal cancer describe their experiences with targeted therapies, chemotherapy, and immunotherapy, highlighting varying outcomes and financial challenges.
Jun 09, 2026
BostonGene announced a strategic collaboration with Daiichi Sankyo to integrate AI-driven analytics into an ADC development program. The company also revealed six abstracts will be presented at the EHA 2026 Congress in Stockholm. The research showcases integrated multiomics and predictive modeling for blood cancer treatment optimization.
